Riboflavin/Dextran

Phase 3Small molecule

CCornea and Laser Eye Institute

Riboflavin/Dextran is one of 12 small molecule programs targeting Keratoconus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconusActive, not recruiting

KeratoconusPhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Keratoconus

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

1 2

Toradol

JJavelin Pharmaceuticals

Approved

1 3

Decadron

AAspen Global Incorporated

Mitosol

Pred Forte

Ricrolin+

IIcahn School of Medicine at Mount Sinai

Phase 3

1 7

Riboflavin/Dextran

CCornea and Laser Eye Institute

Phase 3

1 8

Hypotonic Riboflavin

CCornea and Laser Eye Institute

Phase 3

1 9

Neoral

Novartis

Preclinical

—10

Riboflavin

CCornea and Laser Eye Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratoconus1 trial

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

Unknown status·CCornea and Laser Eye Institute·Phase 3·NCT01152541·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Riboflavin/Dextran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Riboflavin/Dextran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Riboflavin/Dextran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cornea and Laser Eye Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCornea and Laser Eye Institute

Riboflavin/Dextran

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratoconus1 trial

References

Drug Info

Quick Facts

Related News